hybridoma technology

Monoclonal Antibodies: from Development to Clinical Application

REVIEWS , ,

YuI Budchanov

Tver’ Medical University, 4 Sovetskaya str., Tver’, Russian Federation, 170000

For correspondence: Yurii Ivanovich Budchanov, 3 1st per. Krasnoi Slobody, Tver’, Russian Federation, 170001; e-mail: budjur@mail.ru

For citation: Budchanov YuI. Monoclonal Antibodies: from Development to Clinical Application. Clinical oncohematology. 2016;9(3):237-44 (In Russ).

DOI: 10.21320/2500-2139-2016-9-3-237-244

ABSTRACT

The development of monoclonal antibodies (MABs) resulted in revolutionary achievements in diagnosing and treating of oncohematological disorders. The review dwells on the history of the development and improved technologies for production of monoclonal antibodies illustrated by anti-CD20-MABs which recognize different epitopes of the CD20 antigens and have a higher antitumor activity. Engineering techniques can contribute to understanding the effector mechanisms of the application of the novel anti-CD20-MABs and are intended for further improvement of the treatment results.

Keywords: monoclonal antibodies, rituximab, ofatumumab, obinutuzumab, hybridoma technology.

Received: January 13, 2016

Accepted: March 17, 2016

Read in PDF (RUS)pdficon

REFERENCES

  1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7. doi: 10.1038/256495a0.
  2. Galfre G. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature. 1977;266(5602):550–2. doi: 10.1038/266550a0.
  3. Гордеева О.Б., Семикина Е.Л. Современные возможности определения группы крови и резус-принадлежности в педиатрической практике. Вопросы диагностики в педиатрии. 2010;2(4):9–16.
    [Gordeeva OB, Semikina EL. Current capabilities of the blood group and Rhesus factor typing in pediatric practice. Voprosy diagnostiki v pediatrii. 2010;2(4):9–16. (In Russ)]
  4. Рагимов А.А., Дашкова Н.Г. Трансфузионная иммунология. М.: МИА, 2004. С. 270.
    [Ragimov AA, Dashkova NG. Transfuzionnaya immunologiya. (Transfusion immunology.) Moscow: MIA Publ.; 2004. pp. 270. (In Russ)]
  5. Freedman A. Follicular lymphoma: 2014 update on diagnosis and management. Am J Hematol. 2014;89(4):429–36. doi: 10.1002/ajh.23674.
  6. Preijers FW, Huys E, Moshaver B. OMIP-010: a new 10-color monoclonal antibody panel for polychromatic immunophenotyping of small hematopoietic cell samples. Cytometry A. 2012;81A(6):453–5. doi: 10.1002/cyto.a.22056.
  7. Тупицын Н.Н., Гривцова Л.Ю., Купрышина Н.А. Иммунодиагностика опухолей крови на основании многоцветных (8 цветов панелей) европейского консорциума по проточной цитометрии (EURO-FLOW). Иммунология гемопоэза. 2015;13(1):31–62.
    [Tupitsyn NN, Grivtsova LYu, Kupryshina NA. Haematopoietic malignancies immune diagnostics based on Euroflow Consortium proposals: 8-color flow cytometry. Immunologiya gemopoeza. 2015;13(1):31–62. (In Russ)]
  8. Тупицын Н.Н. Иммунология клеток крови. В кн.: Гематология. Национальное руководство. Под ред. О.А. Рукавицына. М.: ГЭОТАР-Медиа, 2015. С. 69–79.
    [Tupitsyn NN. Blood cell immunology. In: Rukavitsyn OA, ed. Gematologiya. Natsional’noe rukovodstvo. (Hematology. National guidelines.) Moscow: GEOTAR-Media Publ.; 2015. pp. 69–79. (In Russ)]
  9. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–57. doi: 10.1038/nri1837.
  10. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol. 2000;27(12):17–24.
  11. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15(9):450–4. doi: 10.1016/0167-5699(94)90276-3.
  12. Renaudineau Y, Devauchelle-Pensec V, Hanrotel C, et al. Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Joint Bone Spine. 2009;76(5):458–63. doi: 10.1016/j.jbspin.2009.03.010.
  13. Martin P, Furman RR, Coleman M, Leonard JP. Phase I to III trials of anti-B cell therapy in non-Hodgkin’s lymphoma. Clin Cancer Res. 2007;13(18):5636–42. doi: 10.1158/1078-0432.ccr-07-1085.
  14. St Clair EW. Novel targeted therapies for autoimmunity. Curr Opin Immunol. 2009;21(6):648–57. doi: 10.1016/j.coi.2009.09.008.
  15. Gurcan H, Keskin D, Stern J, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9(1):10–25. doi: 10.1016/j.intimp.2008.10.004.
  16. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One. 2013;8(7):e66308. doi: 10.1371/journal.pone.0066308.
  17. Otukesh H, Hoseini R, Rahimzadeh N, Fazel M. Rituximab in the treatment of nephrotic syndrome: a systematic review. Iran J Kidney Dis. 2013;7(4):249–56. doi: 10.13172/2053-0293-1-1-480.
  18. Morrison VA. Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies. Clin Infect Dis. 2014;59(5):360–4. doi: 10.1093/cid/ciu592.
  19. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013;11(1):88. doi: 10.1186/1741-7015-11-88.
  20. Bhandari PR, Pai VV. Novel applications of Rituximab in dermatological disorders. Indian Dermatol Online J. 2014;5(3):250–9. doi: 10.4103/2229-5178.137766.
  21. Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol. 2012;5(1):64. doi: 10.1186/1756-8722-5-64.
  22. Rioufol C, Salles G. Obinutuzumab for chronic lymphocytic leukemia. Expert Rev Hematol. 2014;7(5):533–43. doi: 10.1586/17474086.2014.953478.
  23. Owen CJ, Stewart DA. Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Ther Adv Hematol. 2015;6(4):161–70. doi: 10.1177/2040620715586528.
  24. Shah A. Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Previously Untreated Chronic Lymphocytic Leukemia. Ann Pharmacother. 2014;48(10):1356–61. doi: 10.1177/1060028014543271.
  25. Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482–91. doi: 10.1182/blood-2013-05-504043.
  26. Shah A. New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab. Ther Clin Risk Manage. 2015;11:1113–22. doi: 10.2147/TCRM.S71839.
  27. Cerquozzi S, Owen C. Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia. Biol Targ Ther. 2015;9:13–22. doi: 10.2147/BTT.S61600.
  28. Seiter K, Mamorska-Dyga A. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia. Clin Interv Aging. 2015;12(10):951–61. doi: 10.2147/cia.s69278.
  29. Алексеев С.М., Капланов К.Д., Иванов Р.А., Черняева Е.В. Современный подход к разработке и исследованию биоаналогов на примере первого российского препарата моноклональных антител — Ацеллбия® (ритуксимаб). Исследования и практика в медицине. 2015;2(1):8–12. doi: 10.17709/2409-2231-2015-2-1-8-12.
    [Alekseev SM, Kaplanov KD, Ivanov RA, Chernyaeva EV. Current approach to development of biosimilar products containing monoclonal antibodies as an active substance – non-clinical studies of the first Russian rituximab biosimilar, Acellbia®. Research’n Practical Medicine Journal. 2015;2(1):8–12. doi: 10.17709/2409-2231-2015-2-1-8-12. (In Russ)]
  30. Tada M, Tatematsu K-I, Ishii-Watabe A, et al. Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori). mAbs. 2015;7(6):1138–50. doi: 10.1080/19420862.2015.1078054.
  31. Gonzalez-Gonzalez E, Alvarez MM, Marquez-Ipina AR, et al. Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. Crit Rev Biotechnol. 2015;26:1–16. doi: 10.3109/07388551.2015.1114465.